Is a Rash on the Legs Common with Nitrofurantoin?
Skin rash is a recognized adverse effect of nitrofurantoin, but it is not specifically common to the legs—when rash occurs, it typically affects multiple body areas rather than being localized to the lower extremities.
Understanding Nitrofurantoin-Associated Rash
According to the FDA drug label, nitrofurantoin can cause various dermatologic reactions including maculopapular, erythematous, or eczematous eruptions, pruritus, and urticaria 1. The label also notes that exfoliative dermatitis and erythema multiforme (including Stevens-Johnson syndrome) have been reported rarely 1.
Frequency and Pattern
The overall incidence of adverse events with nitrofurantoin ranges from 23-34% in clinical trials, but these predominantly include gastrointestinal symptoms (nausea, headache) rather than dermatologic reactions 2. When skin reactions do occur with nitrofurantoin, they are typically:
- Generalized rather than localized: Case reports describe rash spreading "all over the body" 3 or affecting "face, limbs and trunk" 4
- Part of systemic reactions: Skin manifestations often occur as part of more serious syndromes rather than isolated leg rash
Serious Dermatologic Syndromes to Consider
While simple rash is uncommon, nitrofurantoin has been associated with several severe cutaneous reactions that warrant immediate recognition:
DRESS Syndrome (Drug Reaction with Eosinophilia and Systemic Symptoms):
- Presents with fever, rash, lymphadenopathy, and eosinophilia 5, 3
- Rash is typically widespread, not localized to legs
- Requires immediate drug discontinuation
Leukocytoclastic Vasculitis:
- Can present with "reticular purpuric plaques with occasional ulceration over both lower limbs, upper limbs and abdomen" 6
- This is the one scenario where leg involvement is prominent
- Associated with systemic complications including renal involvement, thrombocytopenia, and hepatic dysfunction 6
ANCA-Associated Vasculitis:
- Rare but documented with renal and skin vasculitis 7
- Symptoms can appear as early as 3 days after starting treatment 7
Subacute Cutaneous Lupus Erythematosus:
- Progressive skin lesions on face, limbs, and trunk 4
- Associated with positive immunology and may require hydroxychloroquine treatment
Clinical Approach
If a patient develops a rash on the legs while taking nitrofurantoin:
Assess for systemic involvement immediately:
- Check vital signs (fever, tachycardia)
- Look for rash extension beyond the legs
- Evaluate for lymphadenopathy
- Check for mucosal involvement
Order laboratory evaluation if systemic features present:
- Complete blood count with differential (eosinophilia, thrombocytopenia)
- Liver function tests
- Renal function tests
- Consider ANCA, ANA if vasculitis suspected
Discontinue nitrofurantoin immediately if:
- Any bullous or exfoliative features 1
- Purpuric lesions suggesting vasculitis
- Systemic symptoms (fever, organ dysfunction)
- Rash is progressive or severe
For mild, isolated leg rash without systemic features:
Important Caveats
Hypersensitivity reactions represent the most frequent spontaneously-reported adverse events in worldwide postmarketing experience with nitrofurantoin 1. However, the specific pattern of isolated leg rash is not a commonly described presentation in either clinical trials or guidelines 9, 2.
The absence of leg-specific rash in major clinical trials 2 and treatment guidelines 2, 8, 9, 10 suggests this is not a typical presentation. When dermatologic reactions occur, they are either generalized or part of serious systemic syndromes requiring immediate intervention.
Do not continue nitrofurantoin in the presence of any unexplained rash, as progression to serious cutaneous reactions, though rare, can occur and may be life-threatening 1, 6.